GLP-1受体激动剂对2型糖尿病患者血管病变影响的研究进展

Abstract
Figure/Table
References (32)
Related Citation (15)

Download: PDF (601 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Type 2 diabetes is a major risk factor of atherosclerotic disease. Thus, the prevention and treatment of diabetic vascular lesions is another important purpose in addition to hypoglycemic for diabetes patients. Exogenous administration of glucagon-like peptide-1 (GLP-1) or GLP-1 receptor agonist is a new kind of antidiabetic drugs, its hypoglycemic effect has been very clear, mainly through the combination with GLP-1 receptors, thereby promoting insulin secretion to reduce blood glucose. In recent years, domestic and foreign studies have found that GLP-1 receptor agonists also have cardiovascular protection. The mechanism may be achieved by improving the function of vascular endothelial cells, antioxidant stress, lowering blood pressure, lowering blood lipid, inhibiting the apoptosis of myocardial cells and so on. However, whether GLP-1 receptor agonists can improve the development of vascular complications in patients with T2DM remains to be confirmed for a long time.

Key words： Glucagon-like peptide-1 receptor GLP-1 receptor agonists Type 2 diabetes mellitus Cardiovascular

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Jingjing1 WEI Li2 WANG Jianbo2

Cite this article:

LIU Jingjing1 WEI Li2 WANG Jianbo2. Research progress of effect of glucagon-like peptide-1 receptor agonists on vascular complications in patients with type 2 diabetes mellitus[J]. 中国医药导报, 2017, 14(18): 38-41.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I18/38

[1] Di Angelantonio E，Kaptoge S，Wormser D，et al. Association of Cardiometabolic Multimorbidity With Mortality [J]. JAMA，2015，314（1）：52-60.
[2] Sarraju A，Kim SH，Knowles JW. Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists [J]. Curr Atherosclerosis Rep，2016，18（2）：7.
[3] Habener JF. The incretin notion and its relevance to diabetes [J]. Endocrinol Meta Clin North Am，1993，22（4）：775-94.
[4] Holst JJ，Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans [J]. Am J Phys Endocrinol Metab，2004，287（2）：E199-E206.
[5] Merida E，Delgado E，Molina L M，et al. Presence of glucagon and glucagon-like peptide-1-（7-36）amide receptors in solubilized membranes of human adipose tissue [J]. J Clin Endocrinol Metab，1993，77（6）：1654-1657.
[6] Chang SY，Kim DB，Ryu GR，et al. Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP/PKA pathway [J]. J Cell Biochem，2013，114（4）：844-853.
[7] Opinto G，Natalicchio A，Marchetti P. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity [J]. Arch Physiol Biochem，2013，119（4）：170-178.
[8] Nauck M. Incretin therapies：highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors [J]. Diabet Obesity Metab，2016，18（3）：203-216.
[9] Mcadam-Marx C，Mukherjee J，Bellows BK，et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data [J]. Diabet Res Clin Pract，2014，103（3）：402-411.
[10] Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes [J]. Exp Opin Pharmacother，2012，13（10）：1451-67.
[11] Nystrom T，Gutniak MK，Zhang Q，et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease [J]. Am J Physiol Endocrinol Metab，2004， 287（6）：E1209-E1215.
[12] 杨威，郑丽丽，李冲，等.艾塞那肽对高糖诱导的内皮细胞凋亡的影响及其作用机制[C]//中华医学会第十二次全国内分泌学学术会议，2013.
[13] Shiraki A，Oyama J，Komoda H，et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells [J]. Atherosclerosis，2012，221（2）：375-382.
[14] Liu H，Dear AE，Knudsen LB，et al. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules [J]. J Endocrinol，2009， 201（1）：59-66.
[15] Pujadas G，De Nigris V，La Sala L，et al. The pivotal role of high glucose-induced overexpression of PKCbeta in the appearance of glucagon-like peptide-1 resistance in endothelial cells [J]. Endocrine，2016，54（2）：396-410.
[16] Brownlee M. The pathobiology of diabetic complications：a unifying mechanism [J]. Diabetes，2005，54（6）：1615-25.
[17] Pugazhenthi S，Qin L，Reddy PH. Common neurodegenerative pathways in obesity，diabetes，and Alzheimer's disease [J]. Biochim Biophys Acta，2017，1863（5）：1037-1045.
[18] Li PC，Liu LF，Jou MJ，et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice [J]. BMC Neurosci，2016，17（1）：37.
[19] 李庆蓉，杨红英.醛糖还原酶与氧化应激对糖尿病外周神经病变影响研究进展[J].国际检验医学杂志，2013， 34（1）：71-73.
[20] An FM，Chen S，Xu Z，et al. Glucagon-like peptide-1 regulates mitochondrial biogenesis and tau phosphorylation against advanced glycation end product-induced neu?鄄ronal insult：Studies in vivo and in vitro [J]. Neurosci?鄄ence，2015，300：75-84.
[21] Wang R，Lu L，Guo Y，et al. Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosis in Human Endothelial Cells and Its Underlying Mechanism [J]. J Cardiovasc Pharmacol，2015， 66（2）：135-140.
[22] Krisai P，Aeschbacher S，Schoen T，et al. Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population [J]. Hypertension（Dallas，Tex：1979），2015，65（2）：306-312.
[23] Kim M，Platt MJ，Shibasaki T，et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure [J]. Nat Med，2013，19（5）：567-575.
[24] Munoz-Barrios S，Guzman-Guzman IP，Munoz-Valle JF，et al. Association of the Hind Ⅲ and S447X polymorphisms in LPL gene with hypertension and type 2 diabetes in Mexican families [J]. Dis Mark，2012，33（6）：313-320.
[25] Petit JM，Cercueil JP，Loffroy R，et al. Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes：The Lira-NAFLD Study [J]. J Clin Endocrinol Metab，2017，102（2）：407-415.
[26] Hein GJ，Baker C，Hsieh J，et al. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production：evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states [J]. Diabetes，2013，62（2）：373-381.
[27] Guo W，Jiang T，Lian C，et al. QKI deficiency promotes FoxO1 mediated nitrosative stress and endoplasmic reticulum stress contributing to increased vulnerability to ischemic injury in diabetic heart [J]. J Mol Cell Cardiol，2014， 75：131-140.
[28] Lonborg J，Vejlstrup N，Kelbaek H，et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction [J]. Eur Heart J，2012，33（12）：1491-1499.
[29] Wu XM，Ou QY，Zhao W，et al. The GLP-1 analogue liraglutide protects cardiomyocytes from high glucose-induced apoptosis by activating the Epac-1/Akt pathway [J]. Exp Clin Endocrinol，122（10）：608-614.
[30] Yi B，Hu X，Wen Z，et al. Exendin-4，a glucagon-like peptide-1 receptor agonist，inhibits hyperglycemia-induced apoptosis in myocytes by suppressing receptor for advanced glycation end products expression [J]. Exp Ther Med，2014，8（4）：1185-1190.
[31] 任焕欣. miR-27a介导GLP-1受体激动剂抑制心肌细胞凋亡作用的机制研究[D].天津：天津医科大学，2016.
[32] Alvarez ML，Khosroheidari M，Eddy E，et al. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis [J]. Atherosclerosis，2015，242（2）：595-604.